The parallel import authorisation is granted for a period of five years. It specifies the differences mentioned in articles R. 5121-117 to R. 5121-119 with the speciality that has obtained marketing authorisation in France. It is published on the Agency’s website.
The Director General of the Agence nationale de sécurité du médicament et des produits de santé sends a copy of the parallel import authorisation to the holder of the marketing authorisation for the medicinal product which has obtained the marketing authorisation in France.